Fig 1. Quantifying PBMC cell-cell interactions perturbed by biologicals.

(a) Example 10x image of cell-cell PBMC subpopulation contacts, with selected contacts highlighted (white circles, scale bar is 25μm). (b) Percent of CD11c⁺ cells in contact with CD3⁺ cells, when naive or after stimulation with VSV or LPS, with or without pre-incubation with MHC-II blocking antibody. (c) CD11c⁺→CD3⁺ interaction scores corresponding to (d). Interaction score is calculated as the observed percentage of A cells in relation to B cells log₂-relative to what is expected if data were randomized. (d) The interaction score of CD19⁺ B-cells→CD56⁺ NK cells (black axis; left), CD19⁺ B-cell counts (purple axis; right), or total PBMC counts (blue axis; far right) as function of increasing rituximab concentration. (e) Interaction scores of (left plot) CD3⁺ T-cells→CD19⁺ B-cells or (right plot) CD3⁺ T-cells→CD20⁺ B-cells (black axis; left), B-cell counts (purple axis; right), or total PBMC counts (blue axis; far right) as function of increasing blinatumomab concentration. (b-c) were performed in triplicate, and representative of three independent experiments; (d-e) were performed in at least 5 technical replicates, and are representative of (d) 5, or (e) 2 repeats over various healthy donors. Average and standard error of means, or boxplots, over technical repeats shown. A t-test was used to determine significance in (b-c).